Inhibition of mTOR by rapamycin can block the development of macrophages and CD4+ T cells in several scenarios, including liver cancer.124, 125 Future studies can make efforts to combine immunity and lipid metabolism, so as to develop novel therapeutic methods that can benefit patients with HCC. This evidence concerns the gene CD4 and hepatocellular carcinoma.